Tevogen Bio Holdings Inc (TVGN)

$5.38 -1.00 (-15.67%)
Market Cap 21.38M
Revenue (ttm) 0.00
Net Income (ttm) -13.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.56
Volume 130,400
Avg Vol 23,641
Day's Range N/A - N/A
Shares Out 3.97M
Stochastic %K 2%
Beta -0.76
Analysts Hold
Price Target $100.00

Company Profile

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 pati...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 838 6436
Website: tevogen.com
Address:
15 Independence Boulevard, Suite #410, Warren, United States
robsmi63
robsmi63 Mar. 14 at 5:33 PM
$TVGN keep posting your news Saadi, it's really helping the sp.
0 · Reply
mark31
mark31 Mar. 13 at 10:36 PM
$TVGN
0 · Reply
NGCS
NGCS Mar. 13 at 9:22 PM
$TVGN Imho stock price should be now 15 usd/sh (0,30 usd before R/S that we had 2 weeks ago), because of today news (AI advances, Insiders´not selling compromise, and only 1% dilution in 12 months if necessary), but also a week ago news (way to a posible 2 companies adquisition: Apozeal /factory/$50 Mil revenue, and Sciometrix/Digital Platform Clinicus). In few months they all mixed could lead Tevogen to reach a x10 market cap (and stock price could move from 75 o 120 usd per share). Do your own diligence, I did mine (this one). Best regards
0 · Reply
NGCS
NGCS Mar. 13 at 9:09 PM
$TVGN 3. The "Recall" Factor (from 87% to 92%) This is arguably more important. Recall is the AI's ability to not miss a good solution. A 92% recall means the AI is almost "infallible" at finding all possible therapeutic targets. It’s like a radar that detects 92% of enemy planes; almost nothing escapes it. 4. Why is this "Gold" for an investor? Intangible Asset: Tevogen is no longer just a "pill" or "injection" company; it is an AI and Software company applied to healthcare. Licensing Potential: In the future, Tevogen could lease this AI to giants like Pfizer or Novartis to help them design their drugs, generating revenue without lifting a finger in a lab. Summary: Tevogen made its "brain" 20% smarter this week. This significantly reduces the risk of future drugs failing in clinical trials because the AI has already "tested" them virtually with nearly 50% exact precision before they even start.
0 · Reply
NGCS
NGCS Mar. 13 at 9:09 PM
$TVGN 2. What does jumping from 40% to 48% precision mean? In biotechnology, this is a massive leap. It means: Fewer "False Positives": Out of every 100 predictions the AI makes, 48 are now direct hits, compared to 40 before. Cost Efficiency: Tevogen will waste 20% less money on experiments that lead nowhere. Speed: By identifying which proteins to target faster, they can design treatments for new COVID variants or new types of cancer in weeks, not months.
0 · Reply
NGCS
NGCS Mar. 13 at 9:08 PM
$TVGN Explaining Tevogen’s AI Precision Leap (from 40% to 48%) This improvement is the "brain" that will allow Tevogen to save hundreds of millions of dollars and years of waiting. Here is a simple breakdown: 1. What does Tevogen’s AI (PredicTcell™) actually do? Imagine the human body is a city and the virus (or cancer) is a hidden intruder. T-cells are the police. The problem is that the body has millions of "doors" (proteins/HLA), and we don’t know exactly which "key" fits the door where the intruder is hiding. Before: Scientists tried "key by key" in the lab (trial and error). It’s incredibly slow and expensive. Now: The AI analyzes millions of data points and tells the scientist: "Don’t try every key; use these 10 because they are the most likely to work."
0 · Reply
ACInvestorBlog
ACInvestorBlog Mar. 13 at 7:20 PM
$TVGN this is good news .... in a normal market with such low float would be gaining more than +20% (extreme oversold as well)
0 · Reply
artinB
artinB Mar. 13 at 6:58 PM
$TVGN is this calm before the storm!!
0 · Reply
ACInvestorBlog
ACInvestorBlog Mar. 13 at 6:55 PM
$TVGN Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization
0 · Reply
artinB
artinB Mar. 13 at 6:53 PM
$TVGN @ACInvestorBlog
0 · Reply
Latest News on TVGN
Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

Mar 13, 2026, 2:45 PM EDT - 2 days ago

Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

Mar 13, 2026, 12:30 PM EDT - 2 days ago

Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

Mar 11, 2026, 3:15 PM EDT - 4 days ago

Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

Tevogen Names Leadership Team to Execute Diversified Growth Strategy

Mar 9, 2026, 7:45 AM EDT - 6 days ago

Tevogen Names Leadership Team to Execute Diversified Growth Strategy

Letter to Shareholders from CEO Dr. Ryan Saadi

Mar 6, 2026, 3:40 PM EST - 9 days ago

Letter to Shareholders from CEO Dr. Ryan Saadi

Tevogen Bio Explores Buyout To Boost Generics Platform

Mar 6, 2026, 12:42 PM EST - 9 days ago

Tevogen Bio Explores Buyout To Boost Generics Platform

Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical

Mar 5, 2026, 2:50 PM EST - 10 days ago

Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical

Tevogen Announces Reverse Stock Split

Mar 4, 2026, 8:00 AM EST - 11 days ago

Tevogen Announces Reverse Stock Split

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization

Feb 27, 2026, 2:20 PM EST - 16 days ago

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization

UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

Feb 26, 2026, 4:22 PM EST - 17 days ago

UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

Feb 26, 2026, 9:20 AM EST - 17 days ago

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders

Jan 30, 2026, 3:00 PM EST - 6 weeks ago

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders

Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue

Jan 29, 2026, 2:45 PM EST - 6 weeks ago

Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue

Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025

Jan 12, 2026, 9:00 AM EST - 2 months ago

Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025

Tevogen CEO Donates Shares to Support Education for Underprivileged Children

Dec 22, 2025, 12:40 PM EST - 2 months ago

Tevogen CEO Donates Shares to Support Education for Underprivileged Children

Tevogen CEO Donates Personal Shares to Support Local Fire Department

Dec 19, 2025, 11:10 AM EST - 3 months ago

Tevogen CEO Donates Personal Shares to Support Local Fire Department

Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company's Shares of Common Stock

Dec 11, 2025, 3:15 PM EST - 3 months ago

Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company's Shares of Common Stock

Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine

Dec 9, 2025, 2:20 PM EST - 3 months ago

Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine

Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook

Dec 8, 2025, 2:50 PM EST - 3 months ago

Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook

Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q

Nov 14, 2025, 2:32 PM EST - 4 months ago

Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q

Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

Nov 5, 2025, 3:20 PM EST - 4 months ago

Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn

Nov 3, 2025, 2:45 PM EST - 4 months ago

Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn

Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress

Oct 29, 2025, 12:35 PM EDT - 4 months ago

Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress

Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

Oct 15, 2025, 3:50 PM EDT - 5 months ago

Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

Sep 25, 2025, 8:30 AM EDT - 6 months ago

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

Sep 23, 2025, 8:30 AM EDT - 6 months ago

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans

Sep 19, 2025, 3:40 PM EDT - 6 months ago

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

Sep 10, 2025, 11:59 AM EDT - 6 months ago

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

Sep 9, 2025, 3:15 PM EDT - 6 months ago

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

Sep 8, 2025, 9:27 AM EDT - 6 months ago

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

Sep 4, 2025, 3:48 PM EDT - 6 months ago

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

Sep 3, 2025, 4:15 PM EDT - 6 months ago

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

Aug 27, 2025, 3:20 PM EDT - 7 months ago

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity

Aug 26, 2025, 2:50 PM EDT - 7 months ago

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

Aug 25, 2025, 3:10 PM EDT - 7 months ago

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

Aug 22, 2025, 3:25 PM EDT - 7 months ago

Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

Aug 19, 2025, 3:40 PM EDT - 7 months ago

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

Aug 19, 2025, 12:10 PM EDT - 7 months ago

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

Aug 18, 2025, 5:50 PM EDT - 7 months ago

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

Aug 18, 2025, 5:15 PM EDT - 7 months ago

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

Aug 14, 2025, 3:55 PM EDT - 7 months ago

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Aug 13, 2025, 3:53 PM EDT - 7 months ago

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

Aug 11, 2025, 3:45 PM EDT - 7 months ago

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

Aug 11, 2025, 1:24 PM EDT - 7 months ago

REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

Aug 11, 2025, 11:58 AM EDT - 7 months ago

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

Aug 11, 2025, 9:28 AM EDT - 7 months ago

REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

Aug 8, 2025, 11:37 AM EDT - 7 months ago

REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy

Aug 7, 2025, 9:00 AM EDT - 7 months ago

Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy

Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

Aug 6, 2025, 3:59 PM EDT - 7 months ago

Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Aug 5, 2025, 2:32 PM EDT - 7 months ago

Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

robsmi63
robsmi63 Mar. 14 at 5:33 PM
$TVGN keep posting your news Saadi, it's really helping the sp.
0 · Reply
mark31
mark31 Mar. 13 at 10:36 PM
$TVGN
0 · Reply
NGCS
NGCS Mar. 13 at 9:22 PM
$TVGN Imho stock price should be now 15 usd/sh (0,30 usd before R/S that we had 2 weeks ago), because of today news (AI advances, Insiders´not selling compromise, and only 1% dilution in 12 months if necessary), but also a week ago news (way to a posible 2 companies adquisition: Apozeal /factory/$50 Mil revenue, and Sciometrix/Digital Platform Clinicus). In few months they all mixed could lead Tevogen to reach a x10 market cap (and stock price could move from 75 o 120 usd per share). Do your own diligence, I did mine (this one). Best regards
0 · Reply
NGCS
NGCS Mar. 13 at 9:09 PM
$TVGN 3. The "Recall" Factor (from 87% to 92%) This is arguably more important. Recall is the AI's ability to not miss a good solution. A 92% recall means the AI is almost "infallible" at finding all possible therapeutic targets. It’s like a radar that detects 92% of enemy planes; almost nothing escapes it. 4. Why is this "Gold" for an investor? Intangible Asset: Tevogen is no longer just a "pill" or "injection" company; it is an AI and Software company applied to healthcare. Licensing Potential: In the future, Tevogen could lease this AI to giants like Pfizer or Novartis to help them design their drugs, generating revenue without lifting a finger in a lab. Summary: Tevogen made its "brain" 20% smarter this week. This significantly reduces the risk of future drugs failing in clinical trials because the AI has already "tested" them virtually with nearly 50% exact precision before they even start.
0 · Reply
NGCS
NGCS Mar. 13 at 9:09 PM
$TVGN 2. What does jumping from 40% to 48% precision mean? In biotechnology, this is a massive leap. It means: Fewer "False Positives": Out of every 100 predictions the AI makes, 48 are now direct hits, compared to 40 before. Cost Efficiency: Tevogen will waste 20% less money on experiments that lead nowhere. Speed: By identifying which proteins to target faster, they can design treatments for new COVID variants or new types of cancer in weeks, not months.
0 · Reply
NGCS
NGCS Mar. 13 at 9:08 PM
$TVGN Explaining Tevogen’s AI Precision Leap (from 40% to 48%) This improvement is the "brain" that will allow Tevogen to save hundreds of millions of dollars and years of waiting. Here is a simple breakdown: 1. What does Tevogen’s AI (PredicTcell™) actually do? Imagine the human body is a city and the virus (or cancer) is a hidden intruder. T-cells are the police. The problem is that the body has millions of "doors" (proteins/HLA), and we don’t know exactly which "key" fits the door where the intruder is hiding. Before: Scientists tried "key by key" in the lab (trial and error). It’s incredibly slow and expensive. Now: The AI analyzes millions of data points and tells the scientist: "Don’t try every key; use these 10 because they are the most likely to work."
0 · Reply
ACInvestorBlog
ACInvestorBlog Mar. 13 at 7:20 PM
$TVGN this is good news .... in a normal market with such low float would be gaining more than +20% (extreme oversold as well)
0 · Reply
artinB
artinB Mar. 13 at 6:58 PM
$TVGN is this calm before the storm!!
0 · Reply
ACInvestorBlog
ACInvestorBlog Mar. 13 at 6:55 PM
$TVGN Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization
0 · Reply
artinB
artinB Mar. 13 at 6:53 PM
$TVGN @ACInvestorBlog
0 · Reply
artinB
artinB Mar. 13 at 6:51 PM
$TVGN the news haven’t been found yet, but now even for quick day trade
0 · Reply
StockNews_Live
StockNews_Live Mar. 13 at 6:45 PM
$TVGN 🎯 STOCK NEWS ALERT 💵 Price: $5.38 (-15.67%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Tevogen Bio Holdings Inc. provided a strategic update regarding its approach to capital management and the continued commitment of its foundational stakeholders. Dr. Manmohan Patel, MD, lead investor… 📎 https://stocknews.live/news/TVGN/tevogen-reaffirms-capital-discipline-64048.html
0 · Reply
ACInvestorBlog
ACInvestorBlog Mar. 13 at 5:57 PM
Added a few shares for next week $TVGN swing trade (risky trade).
0 · Reply
MrAlientrader
MrAlientrader Mar. 13 at 5:21 PM
$TVGN released two good news and both made big drops which indicate someone want cheap shares, likely underwriters want the cheapest offering? Otherwise can’t explain why they so keen to short the price down with no hesitate
0 · Reply
mark31
mark31 Mar. 13 at 5:20 PM
$TVGN
0 · Reply
MrAlientrader
MrAlientrader Mar. 13 at 5:11 PM
$TVGN something bad is brewing, Dilution for the acquisition?
0 · Reply
ACInvestorBlog
ACInvestorBlog Mar. 13 at 5:00 PM
$TVGN beaten down small AI bio name on watch. Free float: 980K shares. Insiders own 78% and SI is at 10% If volume comes in, this one can blow up imho
0 · Reply
ACInvestorBlog
ACInvestorBlog Mar. 13 at 4:32 PM
$TVGN Tevogen AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure
0 · Reply
StockNews_Live
StockNews_Live Mar. 13 at 4:30 PM
$TVGN 🎯 STOCK NEWS ALERT 💵 Price: $6.39 (+0.16%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Tevogen announced performance advancements for its artificial intelligence platform, Tevogen.AI, which solves a critical challenge in drug development by identifying biological targets likely to work… 📎 https://stocknews.live/news/TVGN/tevogen-ai-reports-advancements-29471.html
0 · Reply
TheTradeXchange
TheTradeXchange Mar. 13 at 4:30 PM
$TVGN TVGNW - Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure
0 · Reply
BEATWALLSTREET
BEATWALLSTREET Mar. 13 at 4:07 AM
$TVGN
0 · Reply
Chamelneon
Chamelneon Mar. 11 at 9:50 PM
$TVGN News just in. Tevogen announces novel vaccine which converts people’s hard earned cash into thin air.
2 · Reply